Key Market Insights:
- Market Size:The global hepatitis therapeutics market was valued at $14.4 billion in 2020 and is expected to reach $19.7 billion by 2030, according to Allied Market Research.
- Growth Drivers:The rising prevalence of hepatitis and its variants, along with new product approvals and launches, are major factors driving market growth.
- Regional Analysis:North America, Europe, Asia-Pacific, and LAMEA are the key regions analyzed for market growth.
- Disease Types:The market is segmented into Hepatitis B, Hepatitis C, and other hepatitis types (A, D, E, and G).
- Drug Classes:The main drug classes include oral antivirals and immune modulators.
- Distribution Channels:The market is further segmented by distribution channels like hospital pharmacies, drug stores & retail pharmacies, and online providers.
- Chronic Hepatitis B (CHB) Market:The global Chronic Hepatitis B (CHB) market was valued at $4.6 billion in 2021 and is projected to reach $6.1 billion by 2031, with a CAGR of 3.0% from 2022 to 2031 according to Allied Market Research.
- Elimination Goal:The World Health Organization (WHO) has set a goal to eliminate viral hepatitis as a public health threat by 2030, aiming for a 90% reduction in new infections and a 65% reduction in mortality.
Hepatitis Therapeutics Market Segmentation
The hepatitis C segment to maintain its leadership status throughout the forecast period
Based on disease type, the hepatitis C segment held the highest market share in 2020, accounting for nearly three-fifths of the global hepatitis therapeutics market, and is estimated to maintain its leadership status throughout the forecast period. Moreover, the same segment is projected to manifest the highest CAGR of 3.5% from 2021 to 2030, owing to growing prevalence of hepatitis C globally and due to new drug launches. The report also includes hepatitis B.
Ask to Our Industry Expert: https://www.alliedmarketresearch.com/purchase-enquiry/14883
The oral antivirals segment to maintain its lead position during the forecast period
Based on drug class, the oral antivirals segment accounted for the largest share in 2020, contributing to 88% of the global hepatitis therapeutics market, and is projected to maintain its lead position during the forecast period. This is due to increase in demand of novel drugs and approval of new drugs. However, the immune modulators segment is expected to portray the largest CAGR of 4.2% from 2021 to 2030.
North America to maintain its dominance by 2030
Based on region, North America held the highest market share in terms of revenue 2020, accounting for more than two-fifths of the global hepatitis therapeutics market. Moreover, the Asia-Pacific region is expected to witness the fastest CAGR of 4.3% during the forecast period, owing to rise in investments in growth in R&D activities and geographic expansion of hepatitis therapeutics companies in this region.
Leading Market Players
- Abbvie Inc.
- Bristol Myers & Squibb
- Cipla Inc.
- Gilead Sciences Inc.
- GlaxoSmithKline Plc.
- Hoffmann-La Roche Ltd.
- Lupin Ltd.
- Merck & Co. Inc.
- Teva Pharmaceutical Industries Ltd.
- Zydus Cadila.
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the market analysis from 2021 to 2031 to identify the prevailing Hepatitis Therapeutics Market Opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global Hepatitis Therapeutics Market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the Hepatitis Therapeutics Market players.
- The report includes the analysis of the regional as well as global trends, key players, market segments, application areas, and market growth strategies.
Read More:
Operating Room Management Market Worth USD 10.0 billion by 2031 at a CAGR of 13.0%
Hemodialysis Market to Reach US$ 111.8 Billion in 2032, Says Allied Market Research
Contact Details:
David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
